Want to see JP:4577 full AI Analyst Report?
4577 Stock Chart & Stats
¥1356.00
-¥13.00(-0.64%)
At close: 4:00 PM EST
¥1356.00
-¥13.00(-0.64%)
Day’s Range― - ―
52-Week Range¥1,120.00 - ¥1,521.00
Previous CloseN/A
Volume21.10K
Average Volume (3M)63.87K
Market Cap
¥38.34B
Enterprise Value¥42.94B
Total Cash (Recent Filing)¥1.87B
Total Debt (Recent Filing)¥10.15B
Price to Earnings (P/E)12.2
Beta0.28
Next Earnings
Oct 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)99.39
Shares Outstanding28,854,880
10 Day Avg. Volume54,390
30 Day Avg. Volume63,866
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.65
Price to Sales (P/S)0.68
P/FCF Ratio6.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.5
Revenue Forecast (FY)¥54.50B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow trailing leverage and a large equity buffer provide durable financial flexibility. This conservatism supports investment in capacity, absorbs demand shocks, and reduces refinancing risk, allowing Daito to pursue CDMO contracts or weather client delays without forcing distress sales or asset cuts.
Return To Positive Free Cash FlowRe-establishing positive operating and free cash flow after multi-year deficits materially improves financial resilience. Sustained FCF enables reinvestment in plant, supports dividends or buybacks, and lowers dependence on external financing—strengthening long-term capital allocation.
CDMO Contract Manufacturing ModelA CDMO/CMO business model generates recurring, contracted revenue and long lead-time client relationships. Structural pharmaceutical outsourcing trends and multi-year supply contracts support revenue visibility, utilization planning, and sticky customer relationships versus transactional product sales.
Bears Say
Sharp TTM Revenue DeclineA ~23% top-line contraction materially weakens utilization and scale economics for manufacturing assets. For a CDMO, lower volumes can erode margins, reduce pricing leverage, and prolong recovery cycles if lost client programs or demand shifts are structural rather than temporary.
Margins Below Prior PeaksSustained lower margins shrink the firm's buffer against cost inflation and revenue volatility. If this reflects a shift toward lower‑margin manufacturing or pricing pressure, it could limit cash available for reinvestment, capital maintenance, and shareholder returns over the medium term.
Moderate Cash Conversion And Working-capital RiskOnly moderate conversion of accounting earnings to cash and sub‑1 operating‑cash/EBIT implies working‑capital timing or receivable risks. In a capital‑intensive CDMO context, uneven cash conversion reduces predictability for capex and dividends and raises vulnerability if revenue volatility persists.
Daito Pharmaceutical Co., Ltd. News
4577 FAQ
What was Daito Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daito Pharmaceutical Co., Ltd. lowest stock price was ¥1120.00 and its highest was ¥1521.00 in the past 12 months.
What is Daito Pharmaceutical Co., Ltd.’s market cap?
Daito Pharmaceutical Co., Ltd.’s market cap is ¥38.34B.
When is Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date is Oct 08, 2026 which is in 83 days.
How were Daito Pharmaceutical Co., Ltd.’s earnings last quarter?
Daito Pharmaceutical Co., Ltd. released its earnings results on Jul 10, 2026. The company reported ¥30.96 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Daito Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daito Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Daito Pharmaceutical Co., Ltd. pay dividends?
Daito Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥22.5 which represents an annual dividend yield of 2.75%. See more information on Daito Pharmaceutical Co., Ltd. dividends here
What is Daito Pharmaceutical Co., Ltd.’s EPS estimate?
Daito Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daito Pharmaceutical Co., Ltd. have?
Daito Pharmaceutical Co., Ltd. has 28,854,880 shares outstanding.
What happened to Daito Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Daito Pharmaceutical Co., Ltd. reported an EPS of ¥30.96 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.241%.
Which hedge fund is a major shareholder of Daito Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4577
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.
Technical Analysis
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―